Scrip
Canada approves once-monthly Actonel treatment
03 June 2009
Becky Debens
Please Login to read the full article.
03 June 2009
Becky Debens
becky.debens@informa.com
Health Canada has approved Sanofi-Aventis and Procter & Gamble's bisphosphonate Actonel 150mg (risedronate sodium), for the once-monthly treatment of postmenopausal osteoporosis.
The decision marks the first and only once-monthly treatment option available in the country, as well as adding...
Please Login to read the full article.
RELATED CONTENT
NEWS
- EU's CHMP recommends Amgen's Prolia for two indications
- NICE to review guidance on Servier's Protelos after legal challenge
- FDA continues "safety review" of potential link between bisphosphonates and fractures
- Bisphosphonates may not increase risk of femoral fractures, study finds
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
